These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 24504545)

  • 1. Population pharmacokinetics of nevirapine in Thai HIV-infected patients.
    Wattanakul T; Avihingsanon A; Manosuthi W; Punyawudho B
    Antivir Ther; 2014; 19(7):651-60. PubMed ID: 24504545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.
    Kappelhoff BS; van Leth F; MacGregor TR; Lange J; Beijnen JH; Huitema AD;
    Antivir Ther; 2005; 10(1):145-55. PubMed ID: 15751772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study.
    Kappelhoff BS; Huitema AD; van Leth F; Robinson PA; MacGregor TR; Lange JM; Beijnen JH;
    HIV Clin Trials; 2005; 6(5):254-61. PubMed ID: 16306032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach.
    Moltó J; Valle M; Miranda C; Cedeño S; Miranda J; Santos JR; Negredo E; Vilaró J; Costa J; Clotet B
    J Antimicrob Chemother; 2008 Oct; 62(4):784-92. PubMed ID: 18593723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals.
    van Heeswijk RP; Veldkamp AI; Mulder JW; Meenhorst PL; Wit FW; Lange JM; Danner SA; Foudraine NA; Kwakkelstein MO; Reiss P; Beijnen JH; Hoetelmans RM
    AIDS; 2000 May; 14(8):F77-82. PubMed ID: 10853971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of darunavir coadministration on nevirapine pharmacokinetics in HIV-infected patients: a population approach.
    Dailly E; Raffi F; Perré P; Martin J; Deslandes G; Jolliet P
    HIV Med; 2009 Oct; 10(9):586-9. PubMed ID: 19486187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals.
    de Maat MM; Huitema AD; Mulder JW; Meenhorst PL; van Gorp EC; Beijnen JH
    Br J Clin Pharmacol; 2002 Oct; 54(4):378-85. PubMed ID: 12392585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetic analysis of a nevirapine-based HIV-1 prevention of mother-to-child transmission program in Uganda to assess the impact of different dosing regimens for newborns.
    Frank M; Harms G; Kunz A; Kloft C
    J Clin Pharmacol; 2013 Mar; 53(3):294-304. PubMed ID: 23444284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
    Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
    Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.
    Schipani A; Wyen C; Mahungu T; Hendra H; Egan D; Siccardi M; Davies G; Khoo S; Fätkenheuer G; Youle M; Rockstroh J; Brockmeyer NH; Johnson MA; Owen A; Back DJ;
    J Antimicrob Chemother; 2011 Jun; 66(6):1332-9. PubMed ID: 21441248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics.
    Svensson E; van der Walt JS; Barnes KI; Cohen K; Kredo T; Huitema A; Nachega JB; Karlsson MO; Denti P
    Br J Clin Pharmacol; 2012 Sep; 74(3):465-76. PubMed ID: 22300396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.
    Arab-Alameddine M; Lubomirov R; Fayet-Mello A; Aouri M; Rotger M; Buclin T; Widmer N; Gatri M; Ledergerber B; Rentsch K; Cavassini M; Panchaud A; Guidi M; Telenti A; Décosterd LA; Csajka C;
    J Antimicrob Chemother; 2014 Sep; 69(9):2489-98. PubMed ID: 24821595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of nevirapine in Malaysian HIV patients: a non-parametric approach.
    Mustafa S; Yusuf WN; Woillard JB; Choon TS; Hassan NB
    Eur J Clin Pharmacol; 2016 Jul; 72(7):831-8. PubMed ID: 27025609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.
    Veldkamp AI; Harris M; Montaner JS; Moyle G; Gazzard B; Youle M; Johnson M; Kwakkelstein MO; Carlier H; van Leeuwen R; Beijnen JH; Lange JM; Reiss P; Hoetelmans RM
    J Infect Dis; 2001 Jul; 184(1):37-42. PubMed ID: 11398107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of nevirapine administration on the pharmacokinetics of dolutegravir in patients infected with HIV-1.
    Dailly E; Allavena C; Grégoire M; Reliquet V; Bouquié R; Billaud E; Hernando H; Bouchez S; Deslandes G; Hall N; Jolliet P; Raffi F
    J Antimicrob Chemother; 2015 Dec; 70(12):3307-10. PubMed ID: 26271944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors.
    Dailly E; Billaud E; Reliquet V; Breurec S; Perré P; Léautez S; Jolliet P; Bourin M; Raffi F
    Eur J Clin Pharmacol; 2004 Jul; 60(5):343-8. PubMed ID: 15156302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION).
    Arasteh K; Ward D; Plettenberg A; Livrozet JM; Orkin C; Cordes C; Guo J; Wang E; Yong CL; Robinson P; Quinson A
    HIV Med; 2012 Apr; 13(4):236-44. PubMed ID: 22136068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosage optimization of treatments using population pharmacokinetic modeling and simulation.
    Guidi M; Arab-Alameddine M; Rotger M; Aouri M; Telenti A; Decosterd LA; Buclin T; Csajka C;
    Chimia (Aarau); 2012; 66(5):291-5. PubMed ID: 22867538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients.
    Elsherbiny D; Cohen K; Jansson B; Smith P; McIlleron H; Simonsson US
    Eur J Clin Pharmacol; 2009 Jan; 65(1):71-80. PubMed ID: 18751690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin.
    Avihingsanon A; Manosuthi W; Kantipong P; Chuchotaworn C; Moolphate S; Sakornjun W; Gorowara M; Yamada N; Yanai H; Mitarai S; Ishikawa N; Cooper DA; Phanuphak P; Burger D; Ruxrungtham K
    Antivir Ther; 2008; 13(4):529-36. PubMed ID: 18672531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.